Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, July 24, 2018
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
[ Tue, Jul 24th 2018
] - WOPRAI
Mon, July 23, 2018
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
[ Mon, Jul 23rd 2018
] - WOPRAI
Sumant Kulkarni Maintained (BIIB) at Strong Buy with Increased Target to $396 on, Jul 23rd, 2018
Sumant Kulkarni of Canaccord Genuity, Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $335 to $396 on, Jul 23rd, 2018.
Sumant has made no other calls on BIIB in the last 4 months.
There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 2 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Skorney of "Baird" Downgraded from Buy to Hold on, Tuesday, July 10th, 2018
- Geoff Meacham of "Barclays" Downgraded from Buy to Hold on, Thursday, April 5th, 2018
These are the ratings of the 2 analyists that currently disagree with Sumant
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $366 on, Friday, July 13th, 2018
- Robyn Karnauskas of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $371 on, Friday, July 6th, 2018
